Patrys Limited (PAB.AX)
- Previous Close
0.0090 - Open
0.0090 - Bid 0.0080 x 166154000
- Ask 0.0090 x 165000000
- Day's Range
0.0090 - 0.0090 - 52 Week Range
0.0060 - 0.0150 - Volume
2,075,883 - Avg. Volume
1,100,999 - Market Cap (intraday)
18.517M - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Feb 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.
www.patrys.comRecent News: PAB.AX
Performance Overview: PAB.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PAB.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PAB.AX
Valuation Measures
Market Cap
18.52M
Enterprise Value
14.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.69
Enterprise Value/Revenue
511.08
Enterprise Value/EBITDA
-2.05
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.36%
Return on Equity (ttm)
-68.99%
Revenue (ttm)
1.7M
Net Income Avi to Common (ttm)
-5.12M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
4.46M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
708.9k
Company Insights: PAB.AX
PAB.AX does not have Company Insights